CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 7,500,000 shares of its common stock in an underwritten offering at a price to the public of $25.50 per share, which would result in aggregate gross proceeds of approximately $191.3 million. Vertex has granted the underwriter an option to purchase up to an additional 1,125,000 shares of Vertex common stock on the same terms and conditions.
